Antigens, CD4

• 

  Subject Areas on Research

  • A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody. 
  • A potential role for Elf-1 in CD4 promoter function. 
  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 
  • A single gp120 residue can affect HIV-1 tropism in macaques. 
  • A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. 
  • AIDS response. 
  • ARF1 regulates Nef-induced CD4 degradation. 
  • Accelerated thymic maturation and autoreactive T cells in bronchopulmonary dysplasia. 
  • An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. 
  • An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. 
  • An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. 
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. 
  • Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. 
  • Association of the adaptor molecule LAT with CD4 and CD8 coreceptors identifies a new coreceptor function in T cell receptor signal transduction. 
  • Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 
  • Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. 
  • Beta-arrestin-2 regulates the development of allergic asthma. 
  • Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches. 
  • Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. 
  • Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. 
  • CD25+CD4+ regulatory T cell migration requires L-selectin expression: L-selectin transcriptional regulation balances constitutive receptor turnover. 
  • CD4 T follicular helper cell dynamics during SIV infection. 
  • CD4 binding to major histocompatibility complex class II antigens induces LFA-1-dependent and -independent homotypic adhesion of B lymphocytes. 
  • CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. 
  • CD4 mimetics sensitize HIV-1-infected cells to ADCC. 
  • CD4 receptor diversity in chimpanzees protects against SIV infection. 
  • CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing CD123 (IL-3 receptor alpha). 
  • CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. 
  • CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. 
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. 
  • COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. 
  • Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism. 
  • Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. 
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. 
  • Characterizing the Switching Thresholds of Magnetophoretic Transistors. 
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 
  • Combined deletion of Id2 and Id3 genes reveals multiple roles for E proteins in invariant NKT cell development and expansion. 
  • Combined immunodeficiency due to the selective absence of CD4 inducer T lymphocytes. 
  • Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. 
  • Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. 
  • Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). 
  • Complete DiGeorge syndrome: persistence of profound immunodeficiency. 
  • Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. 
  • Con A-induced suppressor cell function depends on the activation of the CD4+CD45RA inducer T cell subpopulation. 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Control of CD4 gene expression: connecting signals to outcomes in T cell development. 
  • Coreceptor signal strength regulates positive selection but does not determine CD4/CD8 lineage choice in a physiologic in vivo model. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Critical roles of RasGRP1 for invariant NKT cell development. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. 
  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 
  • Cytochalasins enhance the proliferation of CD4 cells through the CD3-Ti antigen receptor complex or the CD2 molecule through an effect on early events of activation. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • Decreased suppressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases. 
  • Deletion of CD4 and CD8 coreceptors permits generation of alphabetaT cells that recognize antigens independently of the MHC. 
  • Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. 
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. 
  • Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies. 
  • Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles. 
  • Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. 
  • Developmental regulation of alpha beta T cell antigen receptor assembly in immature CD4+CD8+ thymocytes. 
  • Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. 
  • Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. 
  • Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. 
  • E protein transcription factors are required for the development of CD4(+) lineage T cells. 
  • Effect of anti-CD4 antibody treatment on inflammatory arthritis in MRL-lpr/lpr mice. 
  • Efficient CD4Cre-Mediated Conditional KRas Expression in Alveolar Macrophages and Alveolar Epithelial Cells Causes Fatal Hyperproliferative Pneumonitis. 
  • Efficient Culture of Human Naive and Memory B Cells for Use as APCs. 
  • Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. 
  • Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. 
  • Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein. 
  • Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. 
  • Epigenetic propagation of CD4 expression is established by the Cd4 proximal enhancer in helper T cells. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Evaluating marker-guided treatment selection strategies. 
  • Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. 
  • Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. 
  • FOXN1 mutation abrogates prenatal T-cell development in humans. 
  • Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. 
  • Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. 
  • Genetically and epidemiologically related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. 
  • Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. 
  • Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection. 
  • HIV entry inhibitors: progress in development and application. 
  • HIV envelope gp120 activates human arterial smooth muscle cells. 
  • HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. 
  • HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. 
  • HLA class II molecules on monocytes regulate T cell proliferation through physical interaction in the CD3 activation pathway. 
  • Hierarchical assembly and disassembly of a transcriptionally active RAG locus in CD4+CD8+ thymocytes. 
  • Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. 
  • Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD4+ cells of lymphocyte or monocyte/macrophage lineages. 
  • Human immunodeficiency virus-1 disease progression in hemophiliacs. 
  • Human interleukin-2 and lymphoproliferative (T-helper cell) responses to soluble HLA class I antigens in vitro: I. Specificity for polymorphic domains. 
  • Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro. 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. 
  • Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. 
  • Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. 
  • Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. 
  • Idiopathic CD4+ T-lymphocytopenia. 
  • Ignoring the obvious missing piece of chronic kidney disease in HIV: cigarette smoking. 
  • Immune checkpoint modulation enhances HIV-1 antibody induction. 
  • Immunoregulatory T cells in cancer immunotherapy. 
  • Impaired function of CD4+/CD25+ T regulatory lymphocytes characterizes the self-limited hepatitis A virus infection. 
  • Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. 
  • Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. 
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction of immunity to human immunodeficiency virus type-1 by vaccination. 
  • Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 
  • Influence of HIV-1 infection and cigarette smoking on leukocyte profile in homosexual men. 
  • Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. 
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. 
  • Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. 
  • Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. 
  • Isolation and structure of antagonists of chemokine receptor (CCR5). 
  • Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 
  • MHC class II alleles associated with clinical and immunological manifestations of HIV-1 infection among children in Catalonia, Spain. 
  • Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. 
  • Modulation of CD45 tyrosine phosphatase activity by antigen. 
  • Modulation of coreceptor transcription during positive selection dictates lineage fate independently of TCR/coreceptor specificity. 
  • Molecular architecture of native HIV-1 gp120 trimers. 
  • Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. 
  • Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. 
  • Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides. 
  • Multiple CTL specificities against autologous HIV-1-infected BLCLs. 
  • Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. 
  • Negative regulation of CD4 gene expression by a HES-1-c-Myb complex. 
  • Neutralization epitopes of the HIV-1 primary isolate DH012. 
  • Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. 
  • Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. 
  • Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 
  • Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Precise arrangement of factor-binding sites is required for murine CD4 promoter function. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. 
  • Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. 
  • Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. 
  • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. 
  • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. 
  • Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. 
  • Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy adult donors. 
  • Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. 
  • Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. 
  • Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. 
  • Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. 
  • Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 
  • Reduction of Stat3 activity attenuates HIV-induced kidney injury. 
  • Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. 
  • Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. 
  • Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR. 
  • Retinal pigment epithelial cells induce foxp3(+) regulatory T cells via membrane-bound TGF-β. 
  • Reversal of the T cell immune system reveals the molecular basis for T cell lineage fate determination in the thymus. 
  • Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. 
  • Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro. 
  • Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. 
  • Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. 
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. 
  • Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. 
  • Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. 
  • Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. 
  • Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development. 
  • Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. 
  • Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. 
  • Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. 
  • Structural rearrangements in the transmembrane glycoprotein after receptor binding. 
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. 
  • Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. 
  • Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Subtractive cloning: new genes for studying inflammatory disorders. 
  • Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. 
  • Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • T cell depletion increases susceptibility to murine cytomegalovirus retinitis. 
  • T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8. 
  • The essential role of LAT in thymocyte development during transition from the double-positive to single-positive stage. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. 
  • The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 
  • The role of ACAID and CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens. 
  • The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. 
  • The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments. 
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. 
  • Thymocytes and cultured thymic epithelial cells express transcripts encoding alpha-3, alpha-5 and beta-4 subunits of neuronal nicotinic acetylcholine receptors: preferential transcription of the alpha-3 and beta-4 genes by immature CD4 + 8 + thymocytes. 
  • Thymocytes and cultured thymic epithelial cells express transcripts encoding alpha-3, alpha-5, and beta-4 subunits of neuronal nicotinic acetylcholine receptors. Preferential transcription of the alpha-3 and beta-4 genes by immature CD4+8+ thymocytes and evidence for response to nicotine in thymocytes. 
  • Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS). 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Treatment of mildly symptomatic human immunodeficiency virus (HIV) infection. 
  • Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. 
  • Upregulation of CD4 expression during MHC class II-specific positive selection is essential for error-free lineage choice. 
  • Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. 
  • Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. 
  • V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. 
• 

  Keywords of People

  • Ciofani, Maria, Associate Professor of Integrative Immunobiology, Cell Biology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Integrative Immunobiology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zhong, Xiaoping, Professor of Pediatrics, Integrative Immunobiology